A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism
This clinical trial evaluated the efficacy of three doses of Gonadorelin acetate administered via the OmniPod pump for ovulation induction in women with primary amenorrhea due to hypogonadotropic hypogonadism. The study was sponsored by Ferring Pharmaceuticals and completed in February 2018.
Indication: Primary Amenorrhea With Hypogonadotropic Hypogonadism
Modality: small molecule
Target: Primary Amenorrhea With Hypogonadotropic Hypogonadism
Sponsor: Ferring Pharmaceuticals
Source URL: ClinicalTrials.gov
Source updated: Mar 03, 2021
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Primary Amenorrhea With Hypogonadotropic Hypogonadism
View original source fields
Condition raw: Primary Amenorrhea With Hypogonadotropic Hypogonadism
Condition normalized: Primary Amenorrhea With Hypogonadotropic Hypogonadism
Modality raw: Primary Amenorrhea With Hypogonadotropic Hypogonadism
Modality normalized: small molecule
Target raw: Primary Amenorrhea With Hypogonadotropic Hypogonadism
Target normalized: Primary Amenorrhea With Hypogonadotropic Hypogonadism